Zymeworks Inc. (ZYME)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Research and development collaborations (note 9) | 48,726 | 27,110 | 16,000 | 19,243 |
| Research and development | 34,449 | 35,738 | 36,353 | 29,163 |
| Impairment on acquired ipr&d (note 6) | - | - | - | 17,287 |
| General and administrative | 14,951 | 16,985 | 13,852 | 15,679 |
| Total operating expenses | 49,400 | 52,723 | 50,205 | 62,129 |
| Loss from operations | -674 | -25,613 | -34,205 | -42,886 |
| Other income, net (note 10) | -621 | 49 | -204 | 114 |
| Interest income | 3,426 | 3,424 | 4,785 | 5,154 |
| Total other income, net | 2,805 | 3,473 | 4,581 | 5,268 |
| Income (loss) before income taxes | 2,131 | -22,140 | -29,624 | -37,618 |
| Income tax recovery (expense) | -186 | 496 | 226 | 68 |
| Net income (loss) | 2,317 | -22,636 | -29,850 | -37,686 |
| Unrealized income (loss) on available for sale securities, net of tax of nil (note 5) | 66 | 546 | 1,905 | -180 |
| Total other comprehensive income (loss) | 66 | 546 | 1,905 | -180 |
| Comprehensive income (loss) | 2,383 | -22,090 | -27,945 | -37,866 |
| Basic (in dollars per share) | 0.03 | -0.3 | -0.39 | -0.49 |
| Basic (in shares) | 75,337,168 | 75,171,020 | 76,128,531 | 76,392,593 |
| Diluted (in dollars per share) | 0.03 | -0.3 | -0.39 | -0.49 |
| Diluted (in shares) | 77,378,449 | 75,226,387 | 76,157,101 | 76,396,217 |